Testing shingles vaccine response when stopping methotrexate in RA
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Infections, Skin clinical trials.
This trial looks at whether pausing methotrexate (a common RA medication) affects how well the shingles vaccine (Shingrix) works for people with rheumatoid arthritis. It may help decide if stopping methotrexate temporarily can improve vaccine protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis (RA) diagnosed by a doctor
- You are 19 years or older
- You are currently taking methotrexate for RA
- You agree to get the shingles vaccine (Shingrix)
- You do not have other types of inflammatory arthritis, active cancer, current infection, or are pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This trial tests different targeted treatments for people with rheumatoid arthritis who have tried one or two biologic or targeted synthetic drugs but still have symptoms. You need to be taking a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.